E. Freed

发表

HIV-1 and the host cell: an intimate association.

E. Freed, 2004, Trends in microbiology.

HIV sequence compendium 2002

B. Korber, Steven Wolinsky, J. Mellors, 2002 .

Association of Human Immunodeficiency Virus Type 1 Gag with Membrane Does Not Require Highly Basic Sequences in the Nucleocapsid: Use of a Novel Gag Multimerization Assay

E. Freed, A. Ono, A. Waheed, 2005, Journal of Virology.

PSGL-1 blocks SARS-CoV-2 S protein-mediated virus attachment and infection of target cells.

K. Kehn-Hall, E. Freed, Brian Hetrick, 2020, bioRxiv : the preprint server for biology.

PSGL-1 inhibits the virion incorporation of SARS-CoV and SARS-CoV-2 spike glycoproteins and impairs virus attachment and infectivity

K. Kehn-Hall, E. Freed, A. Waheed, 2020, bioRxiv.

PSGL-1 Inhibits the Incorporation of SARS-CoV and SARS-CoV-2 Spike Glycoproteins into Pseudovirions and Impairs Pseudovirus Attachment and Infectivity

K. Kehn-Hall, E. Freed, A. Waheed, 2020, Viruses.

Phosphorylation of Residue 131 of HIV-1 Matrix Is Not Required for Macrophage Infection

E. Freed, G. Englund, F. Maldarelli, 1997, Cell.

Cellular Motor Protein KIF-4 Associates with Retroviral Gag

S. Goff, E. Freed, H. Morse, 1999, Journal of Virology.

Mutational analysis of the fusion peptide of the human immunodeficiency virus type 1: identification of critical glycine residues.

J. Bonifacino, E. Freed, M. Delahunty, 1996, Virology.

HIV-1 Matrix Trimerization-Impaired Mutants Are Rescued by Matrix Substitutions That Enhance Envelope Glycoprotein Incorporation

E. Freed, E. Barklis, V. KewalRamani, 2019, Journal of Virology.

Mutation of Dileucine-Like Motifs in the Human Immunodeficiency Virus Type 1 Capsid Disrupts Virus Assembly, Gag-Gag Interactions, Gag-Membrane Binding, and Virion Maturation

K. Nagashima, E. Freed, A. Joshi, 2006, Journal of Virology.

PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing

David E. Martin, E. Freed, J. Orenstein, 2003, Proceedings of the National Academy of Sciences of the United States of America.

HIV-1 Maturation Inhibitor Bevirimat Stabilizes the Immature Gag Lattice

A. Steven, E. Freed, J. Heymann, 2010, Journal of Virology.

Multifunctional RNA Nanoparticles

Wade W Grabow, Wade W. Grabow, W. Chiu, 2014, Nano letters.

The Use of Minimal RNA Toeholds to Trigger the Activation of Multiple Functionalities.

E. Freed, B. Shapiro, E. Bindewald, 2016, Nano letters.

IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein

E. Freed, Shilei Ding, T. Swartz, 2015, Cell Reports.

Determinants of activity of the HIV-1 maturation inhibitor PA-457.

David E. Martin, E. Freed, K. Salzwedel, 2006, Virology.

Antiviral activity of α-helical stapled peptides designed from the HIV-1 capsid dimerization domain

A. Debnath, D. Cowburn, E. Freed, 2011, Retrovirology.

Identification of a Structural Element in HIV-1 Gag Required for Virus Particle Assembly and Maturation

Dennis C Winkler, S. Sarafianos, A. Steven, 2018, mBio.

A Two-Pronged Structural Analysis of Retroviral Maturation Indicates that Core Formation Proceeds by a Disassembly-Reassembly Pathway Rather than a Displacive Transition

A. Steven, E. Freed, N. Cheng, 2013, Journal of Virology.

Structural and Functional Insights into the HIV-1 Maturation Inhibitor Binding Pocket

K. Nagashima, S. Durell, E. Freed, 2012, PLoS pathogens.

A second-site suppressor significantly improves the defective phenotype imposed by mutation of an aromatic residue in the N-terminal domain of the HIV-1 capsid protein.

K. Nagashima, E. Freed, I. Hewlett, 2007, Virology.

Relationship between Human Immunodeficiency Virus Type 1 Gag Multimerization and Membrane Binding

E. Freed, A. Ono, D. Demirov, 2000, Journal of Virology.

HIV-1 infection of non-dividing cells

E. Freed, M. Martin, Malcolma . Martin, 1994, Nature.

HIV-1 INFECTION OF NON-DIVIDING CELLS. AUTHORS' REPLY

M. Emerman, M. Bukrinsky, E. Freed, 1994 .

Impact of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors on Evolution of Resistance to the Maturation Inhibitor Bevirimat (PA-457)

E. Freed, Kayoko Waki, K. Salzwedel, 2009, Journal of Virology.

A Single Polymorphism in HIV-1 Subtype C SP1 Is Sufficient To Confer Natural Resistance to the Maturation Inhibitor Bevirimat

E. Freed, S. Chakravarty, K. Salzwedel, 2011, Antimicrobial Agents and Chemotherapy.

Researchin Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1maturation inhibitor bevirimat

E. Freed, K. Salzwedel, C. Adamson, 2010 .

Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120

E. Freed, M. Martin, Malcolma . Martin, 1994, Journal of virology.

Retroviruses 2004: Review of the 2004 Cold Spring Harbor Retroviruses conference

E. Freed, S. Ross, 2004, Retrovirology.

HIV-1 packs in PACSIN2 for cell-to-cell spread

E. Freed, R. Van Duyne, 2018, Proceedings of the National Academy of Sciences.

Site-specific Mutations in HIV-1 gp41 Reveal a Correlation between HIV-1-mediated Bystander Apoptosis and Fusion/Hemifusion*

E. Freed, H. Garg, R. Blumenthal, 2007, Journal of Biological Chemistry.

ARRDC1 as a mediator of microvesicle budding

E. Freed, Lillian S. Kuo, 2012, Proceedings of the National Academy of Sciences.

Genomic tagging of endogenous human ESCRT-I complex preserves ESCRT-mediated membrane-remodeling functions

E. Freed, S. V. van Engelenburg, Huxley K. Hoffman, 2019, The Journal of Biological Chemistry.

Structural and Mechanistic Studies of the Rare Myristoylation Signal of the Feline Immunodeficiency Virus.

M. Summers, E. Freed, S. Ablan, 2020, Journal of molecular biology.

The Role of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins in Virus Infection (*)

E. Freed, M. Martin, Malcolma . Martin, 1995, The Journal of Biological Chemistry.

The cell biology of HIV-1 and other retroviruses

E. Freed, A. Mouland, Eric O Freed, 2006, Retrovirology.

Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane.

K. Nagashima, S. Lockett, E. Freed, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Depletion of cellular cholesterol inhibits membrane binding and higher-order multimerization of human immunodeficiency virus type 1 Gag.

E. Freed, A. Ono, A. Waheed, 2007, Virology.

The viral protein U (Vpu)-interacting host protein ATP6V0C down-regulates cell-surface expression of tetherin and thereby contributes to HIV-1 release

E. Freed, A. Waheed, Ali G Khan, 2020, The Journal of Biological Chemistry.

The Vpu-interacting protein ATP6V0C regulates expression of tetherin and HIV-1 release

E. Freed, A. Waheed, Ali G Khan, 2020, bioRxiv.

High-Mannose But Not Complex-Type Glycosylation of Tetherin Is Required for Restriction of HIV-1 Release

E. Freed, A. Waheed, Maya Swiderski, 2018, Viruses.

Structure‐based in silico identification of ubiquitin‐binding domains provides insights into the ALIX‐V:ubiquitin complex and retrovirus budding

H. Wolfson, Shay Artzi, E. Freed, 2013, The EMBO journal.

Mechanisms of enveloped virus release.

E. Freed, 2004, Virus research.

Preface

E. Freed, K. Lan, Z. Shí, 2019, Virologica Sinica.

Wild-Type and YMDD Mutant Murine Leukemia Virus Reverse Transcriptases Are Resistant to 2 9 ,3 9 -Dideoxy-3 9 -Thiacytidine

V. Pathak, E. Freed, E. Svarovskaia, 2000 .

Wild-Type and YMDD Mutant Murine Leukemia Virus Reverse Transcriptases Are Resistant to 2′,3′-Dideoxy-3′-Thiacytidine

V. Pathak, E. Freed, E. Svarovskaia, 2000, Journal of Virology.

Myosin-X is essential to the intercellular spread of HIV-1 Nef through tunneling nanotubes

E. Freed, K. Gousset, A. Waheed, 2018, Journal of Cell Communication and Signaling.

Effects of Gag Mutation and Processing on Retroviral Dimeric RNA Maturation

K. Nagashima, W. Fu, V. Pathak, 2006, Journal of Virology.

Complex I polymorphisms, bigenomic heterogeneity, and family history in Virginians with Parkinson's disease

E. Freed, R. Swerdlow, B. Worrall, 2006, Journal of the Neurological Sciences.

Binding of Human Immunodeficiency Virus Type 1 Gag to Membrane: Role of the Matrix Amino Terminus

E. Freed, A. Ono, Akira Ono, 1999, Journal of Virology.

TIM-family proteins inhibit HIV-1 release

Marc C. Johnson, E. Freed, P. Rennert, 2014, Proceedings of the National Academy of Sciences.

Evidence of a Role for Soluble N-Ethylmaleimide-sensitive Factor Attachment Protein Receptor (SNARE) Machinery in HIV-1 Assembly and Release*

E. Freed, H. Garg, A. Joshi, 2011, The Journal of Biological Chemistry.

Antiviral innate immunity: editorial overview.

E. Freed, M. Gale, 2014, Journal of molecular biology.

Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets.

E. Freed, C. Adamson, 2009, Molecular interventions.

Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope glycoprotein precursor gp160

E. Freed, R. Risser, D. Myers, 1989, Journal of virology.

A stable immature lattice packages IP6 for HIV capsid maturation

A. Saiardi, J. Briggs, E. Freed, 2021, Science Advances.

A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity.

E. Delwart, E. Freed, A. Panganiban, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Mutations in the HIV-1 envelope glycoprotein can broadly rescue blocks at multiple steps in the virus replication cycle

K. Fujii, E. Freed, P. Pham, 2019, Proceedings of the National Academy of Sciences.

Resistance to Second-Generation HIV-1 Maturation Inhibitors

David E. Martin, S. Durell, E. Freed, 2018, Journal of Virology.

Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain

C. Petropoulos, E. Freed, A. Waheed, 2015, Journal of Virology.

Functional role of Alix in HIV-1 replication.

K. Nagashima, K. Fujii, E. Freed, 2009, Virology.

TIM-mediated inhibition of HIV-1 release is antagonized by Nef but potentiated by SERINC proteins

A. Feizpour, B. Reinhard, Steven Lin, 2019, Proceedings of the National Academy of Sciences.

Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41.

E. Freed, R. Risser, D. Myers, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Defects in Human Immunodeficiency Virus Budding and Endosomal Sorting Induced by TSG101 Overexpression

E. Freed, J. Orenstein, A. Ono, 2003, Journal of Virology.

The role of envelope glycoprotein processing in murine leukemia virus infection

E. Freed, R. Risser, 1987, Journal of virology.

Inhibition of Human Immunodeficiency Virus Type 1 Assembly and Release by the Cholesterol-Binding Compound Amphotericin B Methyl Ester: Evidence for Vpu Dependence

K. Nagashima, E. Freed, A. Ono, 2008, Journal of Virology.

Inhibition of Human Immunodeﬁciency Virus Type 1 Assembly and Release by the Cholesterol-Binding Compound Amphotericin B Methyl Ester: Evidence for Vpu Dependence (cid:1)

K. Nagashima, E. Freed, A. Waheed, 2008 .

Rafting through the palms: S-acylation of SARS-CoV-2 spike protein induces lipid reorganization

E. Freed, A. Banerjee, Géraldine Vilmen, 2021, Developmental Cell.

Differential glycosylation, virion incorporation, and sensitivity to neutralizing antibodies of human immunodeficiency virus type 1 envelope produced from infected primary T-lymphocyte and macrophage cultures

E. Freed, M. Martin, M. Cho, 1996, Journal of virology.

Trimer Enhancement Mutation Effects on HIV-1 Matrix Protein Binding Activities

E. Freed, E. Barklis, P. Tedbury, 2016, Journal of Virology.

HIV-1 Gag trafficking

E. Freed, A. Joshi, 2007 .

Identification and characterization of fusion and processing domains of the human immunodeficiency virus type 2 envelope glycoprotein

E. Freed, D. Myers, 1992, Journal of virology.

Transport of Human Immunodeficiency Virus Type 1 Pseudoviruses across the Blood-Brain Barrier: Role of Envelope Proteins and Adsorptive Endocytosis

S. M. Robinson, W. Banks, E. Freed, 2001, Journal of Virology.

SERINC proteins potentiate antiviral type I IFN production and proinflammatory signaling pathways

E. Freed, Haitao Wen, Tianliang Li, 2020, Science Signaling.

M A immunodeficiency virus type 1 . of monocyte-derived macrophages by human Integration is required for productive infection

A. Engelman, E. Freed, M. Englund, 1995 .

An Alix Fragment Potently Inhibits HIV-1 Budding

K. Nagashima, J. Hurley, E. Freed, 2006, Journal of Biological Chemistry.

Methods for the study of HIV-1 assembly.

E. Freed, A. Ono, A. Waheed, 2009, Methods in molecular biology.

HIV-1 is dependent on its immature lattice to recruit IP6 for mature capsid assembly

A. Saiardi, E. Freed, L. James, 2023, Nature Structural & Molecular Biology.

Photoinduced reactivity of the HIV-1 envelope glycoprotein with a membrane-embedded probe reveals insertion of portions of the HIV-1 Gp41 cytoplasmic tail into the viral membrane.

T. Veenstra, E. Freed, R. Blumenthal, 2008, Biochemistry.

HIV-1 gag proteins: diverse functions in the virus life cycle.

E. Freed, E O Freed, 1998, Virology.

Myosin-X is essential to the intercellular spread of HIV-1 Nef through tunneling nanotubes

E. Freed, K. Gousset, A. Waheed, 2018, Journal of Cell Communication and Signaling.

Effect of Mutations in the Human Immunodeficiency Virus Type 1 Protease on Cleavage of the gp41 Cytoplasmic Tail

E. Freed, E. Chertova, A. Waheed, 2009, Journal of Virology.

Integration is required for productive infection of monocyte-derived macrophages by human immunodeficiency virus type 1

A. Engelman, E. Freed, M. Martin, 1995, Journal of virology.

Multiple Roles of HIV-1 Capsid during the Virus Replication Cycle

E. Freed, Yulan Zhang, Ke Peng, 2019, Virologica Sinica.

HIV-1 gag: an emerging target for antiretroviral therapy.

E. Freed, Eric O Freed, Philip R Tedbury, 2015, Current topics in microbiology and immunology.

HIV type 1 Gag as a target for antiviral therapy.

E. Freed, A. Waheed, 2012, AIDS research and human retroviruses.

Novel approaches to inhibiting HIV-1 replication.

E. Freed, C. Adamson, 2010, Antiviral research.

HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation.

E. Freed, M. Checkley, B. Luttge, 2011, Journal of molecular biology.

The cytoplasmic tail of retroviral envelope glycoproteins.

E. Freed, P. Tedbury, 2015, Progress in molecular biology and translational science.

p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease

E. Freed, J. Orenstein, M. Martin, 1995, Journal of virology.

Proceedings of the Frontiers of Retrovirology Conference 2016

R. König, D. Elleder, R. Sachidanandam, 2016, Retrovirology.

Transformation of NIH 3T3 cells by cotransfection with c-src and nuclear oncogenes

E. Freed, D. Shalloway, P. J. Johnson, 1987, Molecular and cellular biology.

Recent progress in antiretrovirals--lessons from resistance.

E. Freed, C. Adamson, 2008, Drug discovery today.

Quenching protein dynamics interferes with HIV capsid maturation

K. Schulten, A. Gronenborn, Peijun Zhang, 2017, Nature Communications.

Human Immunodeficiency Virus Type 1 N-Terminal Capsid Mutants That Exhibit Aberrant Core Morphology and Are Blocked in Initiation of Reverse Transcription in Infected Cells

E. Freed, J. G. Levin, Shixing Tang, 2001, Journal of Virology.

Human Apolipoprotein B mRNA-editing Enzyme-catalytic Polypeptide-like 3G (APOBEC3G) Is Incorporated into HIV-1 Virions through Interactions with Viral and Nonviral RNAs*

V. Pathak, Wei-Shau Hu, E. Freed, 2004, Journal of Biological Chemistry.

NMR Structure of the Myristylated Feline Immunodeficiency Virus Matrix Protein

M. Summers, E. Freed, Janae L Baptiste, 2015, Viruses.

Advances in HIV-1 Assembly and Release

E. Freed, 2013, Springer New York.

Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions

E. Freed, M. Martin, Malcolma . Martin, 1996, Journal of virology.

Novel targets for HIV therapy.

W. Greene, E. Freed, Y. Ikeda, 2008, Antiviral research.

Crystallographic and functional analysis of the ESCRT-I /HIV-1 Gag PTAP interaction.

J. Bonifacino, J. Hurley, E. Freed, 2010, Structure.

Late Domain-Dependent Inhibition of Equine Infectious Anemia Virus Budding

E. Freed, R. Montelaro, M. Shehu-Xhilaga, 2004, Journal of Virology.

Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function

E. Freed, J. Orenstein, A. Ono, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Rab27a controls HIV-1 assembly by regulating plasma membrane levels of phosphatidylinositol 4,5-bisphosphate

E. Freed, P. Benaroch, C. Banchio, 2015, The Journal of cell biology.

Dual-acting stapled peptides target both HIV-1 entry and assembly

A. Debnath, M. Summers, E. Freed, 2013, Retrovirology.

A cell-penetrating helical peptide as a potential HIV-1 inhibitor.

A. Debnath, D. Cowburn, E. Freed, 2008, Journal of molecular biology.

Cell-Type-Dependent Targeting of Human Immunodeficiency Virus Type 1 Assembly to the Plasma Membrane and the Multivesicular Body

E. Freed, A. Ono, Akira Ono, 2004, Journal of Virology.

Role of the Gag Matrix Domain in Targeting Human Immunodeficiency Virus Type 1 Assembly

E. Freed, J. Orenstein, A. Ono, 2000, Journal of Virology.

Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production

E. Freed, J. Orenstein, M. Martin, 1994, Journal of virology.

Genetic Evidence for an Interaction between Human Immunodeficiency Virus Type 1 Matrix and α-Helix 2 of the gp41 Cytoplasmic Tail

E. Freed, T. Murakami, 2000, Journal of Virology.

The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions.

E. Freed, T. Murakami, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix

E. Freed, M. Martin, Malcolma . Martin, 1995, Journal of virology.

Analysis of HIV-1 envelope mutants and pseudotyping of replication-defective HIV-1 vectors by genetic complementation.

E. Delwart, E. Freed, A. Panganiban, 1992, AIDS research and human retroviruses.

Activation of different split functionalities upon re-association of RNA-DNA hybrids

S. Lockett, L. Jaeger, E. Freed, 2013, Nature nanotechnology.

Plasma Membrane Anchoring and Gag:Gag Multimerization on Viral RNA Are Critical Properties of HIV-1 Gag Required To Mediate Efficient Genome Packaging

Jianbo Chen, O. Nikolaitchik, Sheldon Tai, 2021, mBio.

HIV-1 Maturation: Lessons Learned from Inhibitors

E. Freed, A. Kleinpeter, 2020, Viruses.

Cellular IP6 Levels Limit HIV Production while Viruses that Cannot Efficiently Package IP6 Are Attenuated for Infection and Replication

A. Saiardi, E. Freed, L. James, 2019, Cell reports.

HIV-1 assembly, release and maturation

E. Freed, Eric O. Freed, 2015, Nature Reviews Microbiology.

Macrophages and Cell-Cell Spread of HIV-1

E. Freed, Kayoko Waki, 2010, Viruses.

Getting IN on Viral RNA Condensation and Virion Maturation

E. Freed, 2016, Cell.

Identification of an HIV-1 Mutation in Spacer Peptide 1 That Stabilizes the Immature CA-SP1 Lattice

A. Steven, E. Freed, J. Fontana, 2015, Journal of Virology.

HIV-1 Replication

E. Freed, E O Freed, 2001, Somatic cell and molecular genetics.

Retrovirus budding.

E. Freed, D. Demirov, 2004, Virus research.

Human immunodeficiency virus type 1 assembly, release, and maturation.

E. Freed, C. Adamson, Catherine S Adamson, 2007, Advances in pharmacology.

Mechanistic Analysis of the Broad Antiretroviral Resistance Conferred by HIV-1 Envelope Glycoprotein Mutations

J. Mellors, E. Freed, Y. Hikichi, 2020, mBio.

Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection

E. Freed, M. Martin, G. Englund, 1995, Journal of virology.

The Late Domain of Human Immunodeficiency Virus Type 1 p6 Promotes Virus Release in a Cell Type-Dependent Manner

E. Freed, J. Orenstein, D. Demirov, 2002, Journal of Virology.

Application of ring-closing metathesis macrocyclization to the development of Tsg101-binding antagonists.

E. Freed, A. Stephen, R. Fisher, 2010, Bioorganic & medicinal chemistry letters.

Viral Late Domains

E. Freed, Eric O. Freed, 2002, Journal of Virology.

The autophagy protein ATG9A promotes HIV-1 infectivity

J. Bonifacino, E. Freed, A. Waheed, 2019, Retrovirology.

S-acylation of SARS-CoV-2 spike protein: Mechanistic dissection, in vitro reconstitution and role in viral infectivity

E. Freed, E. Christenson, Robbins Puthenveetil, 2021, Journal of Biological Chemistry.

Molecular Characterization of Feline Immunodeficiency Virus Budding

K. Nagashima, E. Freed, A. Stephen, 2007, Journal of Virology.

The Role of Lipids in Retrovirus Replication

E. Freed, A. Waheed, 2010, Viruses.

Lipids and membrane microdomains in HIV-1 replication.

E. Freed, A. Waheed, 2009, Virus research.

HIV-1 escape from the entry-inhibiting effects of a cholesterol-binding compound via cleavage of gp41 by the viral protease

E. Freed, E. Chertova, A. Waheed, 2007, Proceedings of the National Academy of Sciences.

Inhibition of HIV-1 Replication by Amphotericin B Methyl Ester

R. Ptak, E. Freed, A. Waheed, 2006, Journal of Biological Chemistry.

Role of lipid rafts in virus replication.

E. Freed, A. Ono, Akira Ono, 2005, Advances in virus research.

Plasma membrane rafts play a critical role in HIV-1 assembly and release

E. Freed, A. Ono, Akira Ono, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Evidence that Productive Human Immunodeficiency Virus Type 1 Assembly Can Occur in an Intracellular Compartment

K. Nagashima, E. Freed, A. Joshi, 2009, Journal of Virology.

Cleavage of the Murine Leukemia Virus Transmembrane Env Protein by Human Immunodeficiency Virus Type 1 Protease: Transdominant Inhibition by Matrix Mutations

E. Freed, R. Kiernan, 1998, Journal of Virology.

Intracellular Reassociation of RNA-DNA Hybrids that Activates RNAi in HIV-Infected Cells.

E. Freed, K. Afonin, Angelica N. Martins, 2017, Methods in molecular biology.

Viroporins: Structures and Functions beyond Cell Membrane Permeabilization

Luis Carrasco, E. Freed, J. Nieva, 2015, Viruses.

The interdomain linker region of HIV-1 capsid protein is a critical determinant of proper core assembly and stability.

Indira Hewlett, Jiyang Jiang, Kunio Nagashima, 2011, Virology.

FIV Gag: virus assembly and host-cell interactions.

E. Freed, B. Luttge, 2010, Veterinary immunology and immunopathology.

New insights into HIV assembly and trafficking.

E. Freed, Muthukumar Balasubramaniam, 2011, Physiology.

Rab11-FIP1C Is Dispensable for HIV-1 Replication in Primary CD4+ T Cells, but Its Role Is Cell Type Dependent in Immortalized Human T-Cell Lines

E. Freed, J. Hultquist, S. V. van Engelenburg, 2022, bioRxiv.

Biochemical evidence of a role for matrix trimerization in HIV-1 envelope glycoprotein incorporation

E. Freed, S. Ablan, P. Tedbury, 2015, Proceedings of the National Academy of Sciences.

Structure of the myristylated human immunodeficiency virus type 2 matrix protein and the role of phosphatidylinositol-(4,5)-bisphosphate in membrane targeting.

K. Nagashima, M. Summers, E. Freed, 2008, Journal of molecular biology.

Enhanced Transmissibility and Decreased Virulence of HIV-1 CRF07_BC May Explain Its Rapid Expansion in China

E. Freed, Shixing Tang, S. Ablan, 2022, Microbiology spectrum.

Real-Time Visualization of HIV-1 GAG Trafficking in Infected Macrophages

K. Nagashima, E. Freed, K. Gousset, 2008, PLoS pathogens.

Distribution of ESCRT Machinery at HIV Assembly Sites Reveals Virus Scaffolding of ESCRT Subunits

Prabuddha Sengupta, Harald F. Hess, Jennifer Lippincott-Schwartz, 2014, Science.

Structural basis for viral late-domain binding to Alix

K. Nagashima, J. Hurley, E. Freed, 2007, Nature Structural &Molecular Biology.

Mechanism of Viral Glycoprotein Targeting by Membrane-Associated RING-CH Proteins

E. Freed, A. Waheed, C. Lun, 2021, mBio.

Mechanism of Viral Glycoprotein Targeting by Membrane-associated-RING-CH Proteins

E. Freed, A. Waheed, C. Lun, 2021, bioRxiv.

Regulation of Human Immunodeficiency Virus Type 1 Env-Mediated Membrane Fusion by Viral Protease Activity

E. Freed, Yuetsu Tanaka, S. Ablan, 2004, Journal of Virology.

Structural and Molecular Determinants of Membrane Binding by the HIV-1 Matrix Protein.

C. Sanders, M. Summers, E. Freed, 2016, Journal of molecular biology.

Myristate exposure in the human immunodeficiency virus type 1 matrix protein is modulated by pH.

P. Prevelige, K. Fujii, E. Freed, 2010, Biochemistry.

Elucidating the Basis for Permissivity of the MT-4 T-Cell Line to Replication of an HIV-1 Mutant Lacking the gp41 Cytoplasmic Tail

E. Freed, S. V. van Engelenburg, Huxley K. Hoffman, 2020, Journal of Virology.

A Single Polymorphism in HIV-1 Subtype C SP1 Is Sufﬁcient To Confer Natural Resistance to the Maturation Inhibitor Bevirimat (cid:1)

E. Freed, S. Chakravarty, K. Salzwedel, 2011 .

In COS Cells Vpu Can Both Stabilize Tetherin Expression and Counteract Its Antiviral Activity

E. Freed, A. Waheed, Nishani Kuruppu, 2014, PloS one.

PSGL-1 restricts HIV-1 infectivity by blocking virus particle attachment to target cells

Zheng Zhou, D. N. Levy, E. Freed, 2020, Proceedings of the National Academy of Sciences.

Generation and validation of a highly sensitive bioluminescent HIV-1 reporter vector that simplifies measurement of virus release

E. Freed, James Kirui, 2020, Retrovirology.

Defects in cellular sorting and retroviral assembly induced by GGA overexpression

K. Nagashima, E. Freed, A. Joshi, 2009, BMC Cell Biology.

HIV‐1 is the causative agent of AIDS, one of the most devastating viral pandemics in history. Although effective treatments are available to suppress HIV‐1 replication in infected patients, current drugs do not eradicate the virus, making life‐long treatment neces‐

E. Freed, 2015 .

Human Immunodeficiency Virus Type 1 N-Terminal Capsid Mutants Containing Cores with Abnormally High Levels of Capsid Protein and Virtually No Reverse Transcriptase

A. Steven, E. Freed, N. Cheng, 2003, Journal of Virology.

Role of Matrix in an Early Postentry Step in the Human Immunodeficiency Virus Type 1 Life Cycle

E. Freed, A. Ono, G. Englund, 1998, Journal of Virology.

, with Retroviral Gag Cellular Motor Protein KIF-4 Associates

S. Goff, E. Freed, H. Morse, 1999 .

The HIV-TSG101 interface: recent advances in a budding field.

E. Freed, 2003, Trends in microbiology.

Virus maturation as a new HIV-1 therapeutic target

E. Freed, K. Salzwedel, C. Adamson, 2009, Expert opinion on therapeutic targets.

The role of matrix in HIV-1 envelope glycoprotein incorporation.

E. Freed, P. Tedbury, 2014, Trends in microbiology.

Rafting with Ebola

E. Freed, 2002, Science.

Point mutations in the HIV-1 matrix protein turn off the myristyl switch.

M. Summers, E. Freed, A. Joshi, 2007, Journal of molecular biology.

1 1 2 EVIDENCE THAT PRODUCTIVE HUMAN IMMUNODEFICIENCY VIRUS 3 TYPE 1 ASSEMBLY CAN OCCUR IN AN INTRACELLULAR 4 COMPARTMENT 5 6 7

K. Nagashima, E. Freed, A. Joshi, 2009 .

GGA and Arf proteins modulate retrovirus assembly and release.

K. Nagashima, J. Bonifacino, E. Freed, 2008, Molecular cell.

HIV-1 Gag: flipped out for PI(4,5)P(2).

E. Freed, 2006, Proceedings of the National Academy of Sciences of the United States of America.

A Mutation in the Human Immunodeficiency Virus Type 1 Gag Protein Destabilizes the Interaction of the Envelope Protein Subunits gp120 and gp41

E. Freed, Jiyang Jiang, C. Aiken, 2006, Journal of Virology.

Reversion of a Human Immunodeficiency Virus Type 1 Matrix Mutation Affecting Gag Membrane Binding, Endogenous Reverse Transcriptase Activity, and Virus Infectivity

E. Freed, A. Ono, R. Kiernan, 1999, Journal of Virology.

Characterization of human immunodeficiency virus type 1 matrix revertants: effects on virus assembly, Gag processing, and Env incorporation into virions

E. Freed, A. Ono, M. Huang, 1997, Journal of virology.

EMBO World Lecture Course ‘Virus–Host: Partners in Pathogenesis’

E. Freed, A. Simon, 2010 .

CryoET structures of immature HIV Gag reveal six-helix bundle

Benjamin A. Himes, Peijun Zhang, E. Freed, 2021, Communications Biology.

Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1maturation inhibitor bevirimat

E. Freed, K. Salzwedel, C. Adamson, 2010, Retrovirology.

Rab 27 a controls HIV-1 assembly by regulating plasma membrane levels of phosphatidylinositol 4 , 5-bisphosphate

E. Freed, P. Benaroch, C. Banchio, 2015 .

Impact of Human Immunodeﬁciency Virus Type 1 Resistance to Protease Inhibitors on Evolution of Resistance to the Maturation Inhibitor Bevirimat (PA-457) (cid:1) †

E. Freed, Kayoko Waki, K. Salzwedel, 2009 .

SAR by Oxime‐Containing Peptide Libraries: Application to Tsg101 Ligand Optimization

E. Freed, A. Stephen, R. Fisher, 2008, Chembiochem : a European journal of chemical biology.

Beyond Tsg101: the role of Alix in 'ESCRTing' HIV-1

J. Hurley, K. Fujii, E. Freed, 2007, Nature Reviews Microbiology.

Functional Replacement of a Retroviral Late Domain by Ubiquitin Fusion

K. Nagashima, E. Freed, A. Joshi, 2008, Traffic.

Single molecule fate of HIV-1 envelope reveals late-stage viral lattice incorporation

E. Freed, S. V. van Engelenburg, J. Aaron, 2018, Nature Communications.

Structural basis of HIV-1 maturation inhibitor binding and activity

A. Gronenborn, E. Freed, J. Perilla, 2022, bioRxiv.

The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation.

Kunio Nagashima, K. Nagashima, E. Freed, 2010, Virology.

In Vitro Resistance to the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PA-457 (Bevirimat)

Kunio Nagashima, K. Nagashima, E. Freed, 2006, Journal of Virology.

Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors

David E. Martin, E. Freed, J. Schneider, 2015, Antimicrobial Agents and Chemotherapy.

HIV-1 Vpu Accessory Protein Induces Caspase-mediated Cleavage of IRF3 Transcription Factor*

J. Bonifacino, E. Freed, A. Waheed, 2014, The Journal of Biological Chemistry.

Dual-acting stapled peptides target both HIV-1 entry and assembly

A. Debnath, M. Summers, E. Freed, 2013, Retrovirology.

Ion-Abrasion Scanning Electron Microscopy Reveals Surface-Connected Tubular Conduits in HIV-Infected Macrophages

Donald Bliss, Terry S. Yoo, Sriram Subramaniam, 2009, PLoS pathogens.

Influenza virus not cRAFTy enough to dodge viperin.

E. Freed, A. Waheed, 2007, Cell host & microbe.

Single molecule fate of HIV-1 envelope reveals late-stage viral lattice incorporation

E. Freed, S. V. van Engelenburg, J. Aaron, 2018, Nature Communications.

Meeting Review: 2018 International Workshop on Structure and Function of the Lentiviral gp41 Cytoplasmic Tail

E. Freed, Melissa V. Fernandez, 2018, Viruses.

Global Rescue of Defects in HIV-1 Envelope Glycoprotein Incorporation: Implications for Matrix Structure

E. Freed, S. Ablan, P. Tedbury, 2013, PLoS pathogens.

A Consensus View of ESCRT-Mediated Human Immunodeficiency Virus Type 1 Abscission.

J. Lippincott-Schwartz, E. Freed, S. V. van Engelenburg, 2017, Annual review of virology.

MicroRNA binding to the HIV-1 Gag protein inhibits Gag assembly and virus production

Antony K. Chen, J. Lippincott-Schwartz, P. Sengupta, 2014, Proceedings of the National Academy of Sciences.

Reevaluation of the Requirement for TIP47 in Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Incorporation

M. Summers, E. Freed, S. Cocklin, 2013, Journal of Virology.

Elucidation of New Binding Interactions with the Tumor Susceptibility Gene 101 (Tsg101) Protein Using Modified HIV-1 Gag-p6 Derived Peptide Ligands.

J. Hurley, E. Freed, A. Stephen, 2011, ACS medicinal chemistry letters.

Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain

E. Freed, E O Freed, D J Myers, 1991, Journal of virology.

Identification of conserved residues in the human immunodeficiency virus type 1 principal neutralizing determinant that are involved in fusion.

E. Freed, R. Risser, Rex Risser, 1991, AIDS research and human retroviruses.

Mechanisms of HIV type 1-induced cognitive impairment: evidence for hippocampal cholinergic involvement with overstimulation of the VIPergic system by the viral coat protein core.

W. Banks, E. Freed, J. Morley, 2002, AIDS research and human retroviruses.

Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy.

H. Masur, E. Freed, A. Ono, 2005, AIDS.

Mutations in the feline immunodeficiency virus envelope glycoprotein confer resistance to a dominant-negative fragment of Tsg101 by enhancing infectivity and cell-to-cell virus transmission.

Prashant B. Panchal, V. Puri, E. Freed, 2014, Biochimica et biophysica acta.

Analysis of HIV-1 Matrix-Envelope Cytoplasmic Tail Interactions

E. Freed, E. Barklis, P. Tedbury, 2019, Journal of Virology.

Authentication Analysis of MT-4 Cells Distributed by the National Institutes of Health AIDS Reagent Program

V. Pathak, E. Freed, K. Delviks-Frankenberry, 2019, Journal of Virology.

Preface

E. Freed, K. Lan, Z. Shí, 2019, Virologica Sinica.

Stabilizes the Immature Gag Lattice HIV-1 Maturation Inhibitor Bevirimat

A. Steven, E. Freed, J. Heymann, 2012 .

Inhibition of neutral sphingomyelinase 2 impairs HIV-1 envelope formation and substantially delays or eliminates viral rebound

F. Kashanchi, P. Calabresi, E. Freed, 2023, Proceedings of the National Academy of Sciences of the United States of America.

The Vpu-interacting Protein SGTA Regulates Expression of a Non-glycosylated Tetherin Species

E. Freed, Y. Ye, A. Waheed, 2016, Scientific Reports.

Effects of second-site mutations on dominant interference by a human immunodeficiency virus type 1 envelope glycoprotein mutant

E. Freed, A. Panganiban, E O Freed, 1995, Journal of virology.

Viral latency and potential eradication of HIV-1

Kenneth A. Matreyek, A. Engelman, E. Freed, 2012, Expert review of anti-infective therapy.

"Expand and Click": A New Method for Labeling HIV-1 Envelope Glycoproteins.

E. Freed, Melissa V. Fernandez, 2017, Cell chemical biology.

CryoET structures of immature HIV Gag reveal a complete six-helix bundle and stabilizing small molecules distinct from IP6

Benjamin A. Himes, Peijun Zhang, E. Freed, 2020, bioRxiv.

Proceedings of the Frontiers of Retrovirology Conference 2016

Sebastian A. Wagner, R. König, D. Elleder, 2016, Retrovirology.

Elucidating the mechanism by which compensatory mutations rescue an HIV-1 matrix mutant defective for gag membrane targeting and envelope glycoprotein incorporation.

M. Summers, E. Freed, Peter Y. Mercredi, 2015, Journal of molecular biology.

Identification of potent maturation inhibitors against HIV-1 clade C

E. Freed, C. Wild, T. J. Nitz, 2016, Scientific Reports.

A Triazinone Derivative Inhibits HIV‐1 Replication by Interfering with Reverse Transcriptase Activity

E. Freed, Kosuke Miyauchi, T. Hoshino, 2016, ChemMedChem.

Elucidation of New Binding Interactions with the Human Tsg101 Protein Using Modified HIV-1 Gag-p6 Derived Peptide Ligands

J. Hurley, E. Freed, A. Stephen, 2011 .

Maturation of HIV-1

E. Freed, Y. Hikichi, 2021, Science.

How to package the RNA of HIV-1

E. Freed, A. Kleinpeter, 2020, eLife.

Elucidation of the Molecular Consequences of Two Unique p6Gag Mutations Derived from HIV-1 CRF07_BC-infected Patients

E. Freed, Shixing Tang, S. Ablan, 2020 .

Studies on the role of the V3 loop in human immunodeficiency virus type 1 envelope glycoprotein function.

S. Chiou, E. Freed, W. Kenealy, 1992, AIDS research and human retroviruses.

Platforms for Personalized Polytherapeutics Discovery in COVID-19

Y. S. Zhang, H. Ebihara, E. Freed, 2021, Journal of Molecular Biology.

Activation of virus uptake through induction of macropinocytosis with a novel polymerizing peptide

P. Wingfield, S. Stahl, E. Freed, 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Multiple Roles of HIV-1 Capsid during the Virus Replication Cycle

E. Freed, Yulan Zhang, Ke Peng, 2019, Virologica Sinica.

Targeting the HIV entry, assembly and release pathways for anti-HIV gene therapy.

K. Nagashima, E. Freed, H. Garg, 2011, Virology.

Authentication analysis of MT-4 cells distributed by the NIH AIDS Reagent Program 1

V. Pathak, E. Freed, K. Delviks-Frankenberry, 2019 .

Hydrazone- and hydrazide-containing N-substituted glycines as peptoid surrogates for expedited library synthesis: application to the preparation of Tsg101-directed HIV-1 budding antagonists.

E. Freed, A. Stephen, R. Fisher, 2006, Organic letters.

The Effect of Inositol Hexakisphosphate on HIV-1 Particle Production and Infectivity can be Modulated by Mutations that Affect the Stability of the Immature Gag Lattice.

A. Saiardi, Peijun Zhang, E. Freed, 2023, Journal of molecular biology.

Cells induced to express a human immunodeficiency virus type 1 envelope gene mutant inhibit the spread of wild-type virus.

E. Freed, A. Panganiban, G. Buchschacher, 1992, Human gene therapy.